Coumarins permeability in Caco-2 cell model

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 2, 2009, Pages 177-184

  Galkin, Anna ^a   Fallarero, Adyary ^b   Vuorela, Pia M ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Caco 2 cells; Coumarins; Cytotoxicity; Permeability

Indexed keywords

4 METHYLESCULETIN; 5,7 DIHYDROXY 4 METHYLCOUMARIN; 5,7 DIMETHOXYCOUMARIN; 6 METHOXY 4 METHYL 2 PYRONE; 6 METHYLCOUMARIN; 7 METHOXY 4 METHYLCOUMARIN; 7,8 DIHYDROXY 4 METHYLCOUMARIN; COUMARIN; COUMARIN DERIVATIVE; DAPHNETIN 7 METHYL ETHER; ESCULIN; FRAXIDIN; HERNIARIN; HYMECROMONE; ISOSCOPOLETIN; PENTOSALEN; SCOPARONE; SCOPOLETIN; UMBELLIFERONE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CULTURE MEDIUM; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG PENETRATION; HUMAN; HUMAN CELL; PKA;

EID: 59049093155     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.02.0006     Document Type: Article

References (31)

1. Härmälä P et al. Strategy for the isolation and identification of coumarins with calcium antagonistic properties from the roots of Angelica archangelica. Phytochem Anal 1992; 3: 42-48.
2. Hoult JR, Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol 1996; 27: 713-722.
3. Kostova I, Mojzis J. Biologically active coumarins as inhibitors of HIV-1. Future HIV Ther 2007; 1: 315-329.
4. Lake BG. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 1999; 37: 423-453.
5. Felter SP et al. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol 2006; 44: 462-475.
6. Kakar SM et al. 6′7′-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004; 75: 569-579.
7. Pelkonen O et al. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144: 139-147.
8. Egan D et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 1990; 22: 503-529.
9. Bailey CA et al. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv Drug Deliv Rev 1996: 22: 85-103.
10. Artursson, P et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001: 46: 27-43.
11. Gan LS, Thakker, D. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 1997; 23: 77-98.
12. Galkin A et al. Miniaturisation and automatisation of Caco-2 permeability studies for screening of natural and synthetic ligands. Planta Med 2006; 11: 995.
13. Galkin A et al. Development of automated 7-day 96-well Caco-2 cell culture model. Die Pharmazie 2008; 63: 464-469.
14. Ishigama M et al. Novel cell proliferation and cytotoxicity assays using a tetrazolium salt that produces a water-soluble formazan dye. In Vitro Toxicol 1995; 8: 187-190.
15. Yang XW et al. Intestinal permeability of antivirus constituents from the fruits of Eucalyptus globulus Labill. in Caco-2 cell model. Bioorg Med Chem Lett 2007; 17: 1107-1111.
16. Riihimäki L et al. Transport properties of bovine and reindeer beta-lactoglobulin in the Caco-2 cell model. Int. J. Pharm. 2008; 347: 1-8.
17. Sharma SD et al. Studies on structure activity relationship of some dihydroxy-4-methylcoumarin antioxidants based on their interaction with Fe(III) and ADP. Biometals 2005; 18: 143-154.
18. Riveiro ME et al. Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells. Bioorg Med Chem 2008; 16: 2665-2675.
19. Rilla K et al. The hyaluronan synthesis inhibitor 4-methylum-belliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol 2004; 123: 708-714.
20. Kramar R, Kaiser E. Effect of imperatorin, a toxic principle from Ammi majus, on energy-transfer in mitochondria. Toxicon 1968; 6: 145-147.
21. FDA: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2000). Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediaterelease solid dosage forms based on a biopharmaceutics classification system, www.fda.gov/cder/guidance/3618fnl.htm (accessed 02 October 2008).
22. Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein- mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 2003; 20: 1200-1209.
23. Arturrson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
24. Pelkonen O et al. The metabolism of coumarin. In: O' Kennedy R, Douglas Thornes R eds. Coumarins. Biology, Applications
25. and Mode of Action, 1st edn. UK: John Wiley & Sons Ltd, 1997: 67-92.
26. Kaul S, Ritschel WA. Studies of the intestinal transfer of coumarin and 7-hydroxycoumarin across guinea pig and rat small intestine. Artzneimittelforschung 1981; 31: 790-795.
27. Camenisch GP et al. A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidominetics. Pharm Res 1998: 15: 1174-1181.
28. Maubon N et al. Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 2007; 21: 659-663.
29. Hazleton LW et al. Toxicity of coumarin. J Pharmacol Exp Ther 1956; 118: 348-358.
30. Mukherji A. Toxicity studies on sporalen, isosporalen and imperatorin in albino rats. J Sci Ind Res 1960; 19: 223-225.
31. Lewis DF et al. Metabolism of coumarin by human P450s: a molecular modelling study. Toxicol In Vitro 2006; 20: 256-264.